Roles of RNA methylation by means of N6-methyladenosine (m6A) in human cancers

• Published in: Cancer letters Vol. 408; pp. 112 - 120
• Main Authors: Wang, Siwei, Sun, Chunxiao, Li, Jianhua, Zhang, Erbao, Ma, Zhifei, Xu, Weizhang, Li, Hong, Qiu, Mantang, Xu, Youtao, Xia, Wenjia, Xu, Lin, Yin, Rong
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.11.2017
• Subjects: Cancer therapy; Human cancers; m6A; N6-methyladenosine; RNA methylation; m6A; N6-methyladenosine; Cancer therapy; RNA methylation; Human cancers
• ISSN: 0304-3835; 1872-7980
• DOI: 10.1016/j.canlet.2017.08.030

Reversible methylation by means of N6-methyladenosine (m6A) is the most prevalent internal modification in mammalian mRNA. This RNA chemical mark is created by proteins that are m6A “writers” and can be reversed by proteins that are m6A “erasers” (i.e., demethylases). Some other proteins serving as “readers” can recognize m6A-containing mRNA and regulate downstream molecular mechanisms accordingly. Although m6A bases in RNA perform critical functions in important biological processes, their roles in cancer biology and cancer stem cells remain largely unknown. In this review, we focus on the m6A-associated mechanisms and modification landscapes in several major malignant tumors. Global and detailed analyses were both conducted on relevant high-throughput sequencing data. Possible interventions against m6A demethylases are also explored in this review, which may be advantageous for the treatment of m6A related cancers. [Display omitted] •N6-methyladenosine (m6A) reversible methylation plays critical roles in human cancers.•m6A IP-seq provides possibilities to clarify m6A-related regulations in malignant tumors.•Studies on m6A RNA methylation provide clues for m6A-targeted therapies.